Evaluation of clinical benefits of treatments for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The need for regulatory approval of new therapies for the treatment of Alzheimer's disease-a progressive neurodegenerative condition-has made the assessment of treatment efficacy an urgent priority for discussion and investigation in the field. In the first part of this Personal View, we summarise current views on what constitutes a clinically meaningful benefit from treatment for Alzheimer's disease, including the concept of a minimum treatment effect against which to compare trial outcomes and its limitations. Considering existing and divergent definitions of clinically meaningful change, we define this concept in the second part of the Personal View by proposing a new approach that consecutively considers whether a treatment benefit for Alzheimer's disease is noticeable, valuable, and worthwhile in the context of costs and risks. This approach could be a useful foundation from which the field can move forwards on this issue and address existing gaps in understanding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Mouelhi, Y., Jouve, E., Castelli, C., & Gentile, S. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01344-w · Cited by 450
Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338
Interpreting patient-reported outcome results: US FDA guidance and emerging methods
McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.12 · Cited by 320
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Self-citationTreatment for Alzheimer's disease
Fox, N. C., Belder, C. R. S., Ballard, C. G., Kales, H. C., Mummery, C. J., Caramelli, P., Ciccarelli, O., Frederiksen, K. S., Gómez‐Isla, T., Ismail, Z., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01329-7 · Cited by 157
Walsh, S., Merrick, R. L., Milne, R., Nurock, S., Richard, E., & Brayne, C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14108 · Cited by 50
“Real-world dilution of a trial efficacy, that is, already below estimated thresholds of minimum clinically meaningful effect 11,12 is unlikely to lead to population benefit.”
Self-citationSarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 46
“Although recent results from anti-amyloid trials demonstrated significant statistical differences favoring treatment over placebo, it remains controversial whether such results are clinically noticeable and valuable 70 .”
Matt, E., Mitterwallner, M., Radjenovic, S., Grigoryeva, D., Weber, A., Stögmann, E., Domitner, A., Zettl, A., Osou, S., & Beisteiner, R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.59170 · Cited by 50
Metadata
- Authors
- Liu, K. Y., Walsh, S., Brayne, C., Merrick, R., Richard, E., & Howard, R.
- Affiliations
- University College London (GB)
- University of Cambridge (GB)
- Radboud University Nijmegen (NL)
- Corresponding author
- Liu, Kathy Y
- Venue
- The Lancet Healthy Longevity
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 4
- Issue
- 11
- Pages
- e645-e651
- ISSN
- 2666-7568 (ISSN-L)
- OpenAlex
- W4388164740
- Cited by
- 31
- References
- 39
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 12 · 2023: 1
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Healthy Longevity (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Funders
- Alzheimer’s Research UK (ARUK-PhD2017–34)
- Medical Research Council (MR/S021418/1)
- National Institute for Health and Care Research
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- Alzheimer's disease, treatment efficacy, regulatory approval, clinical trial results, cost-effectiveness, risk-benefit assessment, neurodegenerative diseases
- MeSH terms
- Alzheimer Disease, Humans, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of clinical benefits of treatments for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/s2666-7568(23)00193-9
- The paper
- Liu, K. Y., Walsh, S., Brayne, C., Merrick, R., Richard, E., & Howard, R. (2023). Evaluation of clinical benefits of treatments for Alzheimer's disease. The Lancet Healthy Longevity. https://doi.org/10.1016/s2666-7568(23)00193-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.